Those forces include manufacturing costs, a less obstructive regulatory path, development of data on adoption of existing biosimilars, a growing number of competitors, and a favorable profitability profile. More
Natpara was recently approved for treatment of hypoparathyroidism in patients who cannot be controlled with calcium and active vitamin D supplementation alone. More
